<DOC>
	<DOC>NCT00353366</DOC>
	<brief_summary>GSK has submitted a registration file for its live attenuated oral human rotavirus (HRV) vaccine in several countries. In view of its registration in the Philippines, the present study will collect data on the safety of the vaccine in the local target population as per the Bureau of Food and Drugs Directive.</brief_summary>
	<brief_title>To Evaluate Safety &amp; Reactogenicity of GSK Bio's Human Rotavirus (HRV) Vaccine in Filipino Infants at Least 6 Weeks of Age at First Vaccination</brief_title>
	<detailed_description>The protocol was amended to reflect a change in the prescribing information. The age of the infants was changed from 6 - 14 weeks to at least 6 weeks at the time of the first vaccination. This protocol posting has been amended in order to comply with FDA AA.</detailed_description>
	<mesh_term>Gastroenteritis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects who the investigator believes that their parents/guardians can and will comply with the requirements of the protocol (e.g. completion of the diary cards, return for followup visits) should be enrolled in the study. A Filipino male or female aged at least 6 weeks at the time of the first vaccination. Written informed consent obtained from the parent or guardian of the subject. History of allergic disease or reactions likely to be exacerbated by any component of the vaccine. Any history of chronic gastrointestinal disease including any uncorrected congenital malformation of the GI tract. Any contraindications as stated in the Prescribing Information.</criteria>
	<gender>All</gender>
	<minimum_age>6 Weeks</minimum_age>
	<maximum_age>24 Weeks</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>safety</keyword>
	<keyword>Post-marketing surveillance (PMS)</keyword>
	<keyword>Rotarix</keyword>
	<keyword>oral</keyword>
	<keyword>Filipino</keyword>
	<keyword>Rotavirus</keyword>
	<keyword>Gastroenteritis</keyword>
	<keyword>Human Rotavirus (HRV) vaccine</keyword>
</DOC>